Gouty arthritis is a chronic inflammatory condition caused by the deposition of urate crystals in joints, resulting in severe pain and swelling. According to Tingfen Han et al., 2024, the global prevalence of gout ranges from 1-4%, with an incidence rate of 0.1-0.3%, increasing with age. The gouty arthritis drug pipeline, as analyzed by Expert Market Research, focuses on novel therapies, including small molecules, biologics, and recombinant enzymes. The growing prevalence, aging populations, and the emphasis on targeted treatment strategies are expected to drive pipeline expansion and market growth in the coming years.
Major companies involved in the gouty arthritis pipeline analysis include Arthrosi Therapeutics, Shanton Pharmaceuticals, and others.
Leading drugs currently in the pipeline include AR882, SAP-001, and others.
The drug pipeline is expanding with advancements in biologics, uric acid–lowering therapies, and recombinant enzymes, driven by rising prevalence, aging populations, and increasing demand for targeted treatment options.
The Gouty Arthritis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into gouty arthritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gouty arthritis. The gouty arthritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gouty arthritis pipeline landscape will include an analysis based on efficacy and safety measures published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gouty arthritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to gouty arthritis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Gouty arthritis is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints, resulting from prolonged hyperuricemia. It occurs when uric acid builds up in the blood and crystallizes, triggering sudden, painful flares, swelling, and joint stiffness.
Gouty arthritis treatments include urate-lowering therapies, xanthine oxidase inhibitors, and uricosuric agents, which help reduce serum uric acid levels, prevent crystal deposition, and manage recurrent flares effectively. In December 2024, Eisai received approval in China for URECE® (Dotinurad), a novel uricosuric drug that selectively inhibits URAT1, lowering serum uric acid levels. Phase 3 trial results demonstrated its superiority over febuxostat, positioning it as a significant advancement in the gouty arthritis drug pipeline.
According to Tingfen Han et al. (2024), the global prevalence of gout ranges from 1%-4%, with an annual incidence rate of 0.1%-0.3%, both increasing with age. Furthermore, according to Helio (August 2024), the number of gout cases are expected to rise by over 70% worldwide, from 55.8 million in 2020 to 95.8 million in 2050. The rise is primarily driven by aging demographics and population growth.
This section of the report covers the analysis of gouty arthritis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The gouty arthritis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 54%, covers a major share of the total gouty arthritis clinical trials, highlighting strong late-stage developments that can significantly drive advancements. Phase II follows with 30%, showing promising mid-stage progress. Phase I and phase IV each account for 7-8%, reflecting steady innovation across early and post-marketing stages. Together, these phases demonstrate a balanced and positive pipeline distribution.
The drug molecule categories covered under the gouty arthritis pipeline analysis include small molecules, biologics, gene therapies, and recombinant enzymes. The gouty arthritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gouty arthritis. Urate-lowering drug therapies are emerging strongly in the gouty arthritis pipeline to provide effective treatment options. For instance, XNW3009, developed by Evopoint Biosciences, is under Phase III evaluation after demonstrating superior uric acid-lowering efficacy compared to Benzbromarone and Febuxostat. The drug achieved up to 90% uric acid target rates, showing strong potential to transform gout management by offering safer and more effective alternatives to existing therapies.
The EMR report for the gouty arthritis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gouty arthritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gouty arthritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for gouty arthritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of gouty arthritis drug candidates.
AR882, a novel and selective URAT1 inhibitor, is being evaluated in a Phase 3 randomized, double-blind, placebo-controlled trial sponsored by Arthrosi Therapeutics. The study is examining its efficacy and safety in reducing serum uric acid levels in gout patients over 12 months. With prior Phase 2 results showing significant urate reduction and tophi regression, AR882 is emerging as a promising therapy aimed at addressing unmet needs in chronic gouty arthritis management.
SAP-001, developed by Shanton Pharmaceuticals, is under evaluation in a Phase 2b randomized, double-blind, placebo-controlled trial for refractory gout. This once-daily oral therapy is designed to lower serum uric acid by targeting a distinct kidney transporter. The study is examining three dosing regimens to assess efficacy, safety, and tolerability, along with reductions in gout flares and tophi. Early findings are showing strong urate-lowering activity, positioning SAP-001 as a promising option for patients unresponsive to conventional therapies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Gouty Arthritis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gouty arthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gouty arthritis collaborations, regulatory environments, and potential growth opportunities.
Psoriatic Arthritis Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share